{
  "pmcid": "5971365",
  "config": {
    "model": "gpt",
    "strategy": "zero-shot"
  },
  "usage": {
    "input": 14043,
    "output": 1290
  },
  "raw_text": "{\n  \"extractions\": [\n    {\n      \"outcome\": \"clinically meaningful improvement at week 144 (\u2a7e3-point increase on the SDMT)\",\n      \"intervention\": \"daclizumab beta\",\n      \"comparator\": \"intramuscular (IM) interferon (IFN) beta-1a\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 188,\n      \"intervention_group_size\": 287,\n      \"comparator_events\": 144,\n      \"comparator_group_size\": 277,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"Symbol Digit Modalities Test (SDMT) score at week 96\",\n      \"intervention\": \"daclizumab beta\",\n      \"comparator\": \"intramuscular (IM) interferon (IFN) beta-1a\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 720,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 682,\n      \"intervention_mean\": 4.1,\n      \"intervention_standard_deviation\": 12.4,\n      \"comparator_mean\": 2.9,\n      \"comparator_standard_deviation\": 12.7\n    },\n    {\n      \"outcome\": \"Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients\",\n      \"intervention\": \"daclizumab beta\",\n      \"comparator\": \"intramuscular (IM) interferon (IFN) beta-1a\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 287,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 277,\n      \"intervention_mean\": 6.3,\n      \"intervention_standard_deviation\": 12.6,\n      \"comparator_mean\": 3.1,\n      \"comparator_standard_deviation\": 13.2\n    },\n    {\n      \"outcome\": \"clinically meaningful worsening at week 96 (\u2a7e3-point decrease on the SDMT)\",\n      \"intervention\": \"daclizumab beta\",\n      \"comparator\": \"intramuscular (IM) interferon (IFN) beta-1a\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 140,\n      \"intervention_group_size\": 720,\n      \"comparator_events\": 169,\n      \"comparator_group_size\": 682,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"clinically meaningful improvement at week 96 (\u2a7e3-point increase on the SDMT)\",\n      \"intervention\": \"daclizumab beta\",\n      \"comparator\": \"intramuscular (IM) interferon (IFN) beta-1a\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 432,\n      \"intervention_group_size\": 720,\n      \"comparator_events\": 369,\n      \"comparator_group_size\": 682,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    }\n  ]\n}",
  "extraction": [
    {
      "outcome": "clinically meaningful improvement at week 144 (\u2a7e3-point increase on the SDMT)",
      "intervention": "daclizumab beta",
      "comparator": "intramuscular (IM) interferon (IFN) beta-1a",
      "outcome_type": "binary",
      "intervention_events": 188,
      "intervention_group_size": 287,
      "comparator_events": 144,
      "comparator_group_size": 277,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5971365"
    },
    {
      "outcome": "Symbol Digit Modalities Test (SDMT) score at week 96",
      "intervention": "daclizumab beta",
      "comparator": "intramuscular (IM) interferon (IFN) beta-1a",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 720,
      "comparator_events": null,
      "comparator_group_size": 682,
      "intervention_mean": 4.1,
      "intervention_standard_deviation": 12.4,
      "comparator_mean": 2.9,
      "comparator_standard_deviation": 12.7,
      "pmcid": "5971365"
    },
    {
      "outcome": "Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients",
      "intervention": "daclizumab beta",
      "comparator": "intramuscular (IM) interferon (IFN) beta-1a",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 287,
      "comparator_events": null,
      "comparator_group_size": 277,
      "intervention_mean": 6.3,
      "intervention_standard_deviation": 12.6,
      "comparator_mean": 3.1,
      "comparator_standard_deviation": 13.2,
      "pmcid": "5971365"
    },
    {
      "outcome": "clinically meaningful worsening at week 96 (\u2a7e3-point decrease on the SDMT)",
      "intervention": "daclizumab beta",
      "comparator": "intramuscular (IM) interferon (IFN) beta-1a",
      "outcome_type": "binary",
      "intervention_events": 140,
      "intervention_group_size": 720,
      "comparator_events": 169,
      "comparator_group_size": 682,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5971365"
    },
    {
      "outcome": "clinically meaningful improvement at week 96 (\u2a7e3-point increase on the SDMT)",
      "intervention": "daclizumab beta",
      "comparator": "intramuscular (IM) interferon (IFN) beta-1a",
      "outcome_type": "binary",
      "intervention_events": 432,
      "intervention_group_size": 720,
      "comparator_events": 369,
      "comparator_group_size": 682,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5971365"
    }
  ]
}